Under the contract, Evotec is expected to use its Screening Platform and proprietary GPCR modeling software for identifying and validating novel modulators against various targets selected by Takeda Cambridge.
Evotec chief operating officer Mario Polywka said they are proud to be selected by Takeda Cambridge to collaborate on this important project.
"We have invested significantly in our hit-identification platform and this alliance further validates the strength of this platform and Evotec’s ability to bring value to its partner’s drug discovery efforts," Polywka said.